AI Model Combines Metadata & Images for Enhanced Skin… : Oncology Times
An abstract is unavailable.
Related Articles
ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR
The phase 3 ARES trial of MaaT013 in third-line GI-aGVHD met its primary end point of GI-ORR at day 28.
TACE Plus Camrelizumab and Rivoceranib Boosts PFS in Unresectable HCC
TACE with camrelizumab and rivoceranib significantly improves PFS in unresectable HCC, per phase 2 CARES-005 study results.
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | NEJM
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive…
Gastrointestinal Cancers Symposium (ASCO GI)
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Patient Considerations for Front-line Systemic Immunotherapies in uHCC.
James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line…
Registration | Society of Gynecologic Oncology
The SGO Annual Meeting on Women’s Cancer® is the premier educational and scientific event for professionals dedicated to advancing gynecologic cancer care. It brings together…
Addition of CRT to Chemotherapy Does Not Improve RFS in Resected Gallbladder Cancer
Relapse-free survival rates were not improved when chemoradiation was added to chemotherapy in resected gallbladder cancer, according to data from the ACCELERATE trial.
RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC
Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.
Certepetide Plus Gemcitabine and Nab-Paclitaxel Shows Preliminary Activity in Metastatic Pancreatic Cancer
Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.
